Carcinoma of an unknown primary site: a chemotherapy strategy based on histological differentiation--results of a prospective study.

[1]  J. Hainsworth,et al.  Overexpression of Her-2 in patients with poorly differentiated carcinoma or poorly differentiated adenocarcinoma of unknown primary site. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  R. Gray,et al.  Sequential biochemical modulation of fluorouracil with folinic acid, N-phosphonacetyl-L-aspartic acid, and interferon alfa-2a in advanced colorectal cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  A. Kaider,et al.  Biochemical modulation of 5-fluorouracil by leucovorin with or without interferon-alpha-2c in patients with advanced colorectal cancer: final results of a randomised phase III study. , 1999, European journal of cancer.

[4]  S. Culine,et al.  Les carcinomes métastatiques d'origine indéterminée , 1998 .

[5]  C. Falkson,et al.  Mitomycin C, Epirubicin and Cisplatin versus Mitomycin C Alone as Therapy for Carcinoma of Unknown Primary Origin , 1998, Oncology.

[6]  S. Culine,et al.  [Metastatic carcinoma of unknown origin]. , 1998, Bulletin du cancer.

[7]  J. Hainsworth,et al.  Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Lokich,et al.  Dose intensity for bolus versus infusion chemotherapy administration: review of the literature for 27 anti-neoplastic agents. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  E. Vokes.  The promise of biochemical modulation in combined modality therapy. , 1994, Seminars in Oncology.

[10]  H. Jd,et al.  Poorly differentiated carcinoma or adenocarcinoma of unknown primary site: long-term results with cisplatin-based chemotherapy. , 1994 .

[11]  G. Daugaard.  Unknown primary tumours. , 1994, Cancer treatment reviews.

[12]  J. Hainsworth,et al.  Poorly differentiated carcinoma or adenocarcinoma of unknown primary site: long-term results with cisplatin-based chemotherapy. , 1994, Seminars in oncology.

[13]  J. Hainsworth,et al.  Treatment of patients with cancer of an unknown primary site. , 1993, The New England journal of medicine.

[14]  J. Hainsworth,et al.  Poorly differentiated neuroendocrine carcinoma of unknown primary tumor site. , 1993, Seminars in oncology.

[15]  J. Sporn,et al.  Empirical chemotherapy for adenocarcinoma of unknown primary tumor site. , 1993, Seminars in oncology.

[16]  R. Lenzi,et al.  The biology of unknown primary tumors. , 1993, Seminars in oncology.

[17]  R. Lenzi,et al.  Phase II study of cisplatin, 5-fluorouracil and folinic acid in patients with carcinoma of unknown primary origin. , 1993, European journal of cancer.

[18]  J. Hainsworth,et al.  Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  R. Schilsky,et al.  Phase I clinical and pharmacologic study of intraperitoneal cisplatin and fluorouracil in patients with advanced intraabdominal cancer. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  J. Verweij,et al.  Carcinoma of unknown primary: identification of a treatable subset? , 1990, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  S. Wadler,et al.  Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  J. Hainsworth,et al.  Peritoneal carcinomatosis of unknown primary site in women. A distinctive subset of adenocarcinoma. , 1989, Annals of internal medicine.

[23]  T. Chevalier,et al.  Early metastatic cancer of unknown primary origin at presentation. A clinical study of 302 consecutive autopsied patients. , 1988, Archives of internal medicine.

[24]  J. Verweij,et al.  5-Fluorouracil, doxorubicin and mitomycin C (FAM) combination chemotherapy for metastatic adenocarcinoma of unknown primary. , 1988, European Journal of Cancer and Clinical Oncology.

[25]  M. Tattersall,et al.  Metastatic adenocarcinoma of unknown primary site. A randomized study of two combination chemotherapy regimens. , 1987, European journal of cancer & clinical oncology.

[26]  R. Goldberg,et al.  5-fluorouracil, adriamycin, and mitomycin in the treatment of adenocarcinoma of unknown primary. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  F. Greco,et al.  The unrecognized extragonadal germ cell cancer syndrome. , 1981, Annals of internal medicine.

[28]  P. Rosen.  Axillary lymph node metastases in patients with occult noninvasive breast carcinoma , 1980, Cancer.

[29]  M. Tattersall,et al.  Metastatic adenocarcinomas of unknown primary site: a randomized study of two combination-chemotherapy regimens. , 1980, The New England journal of medicine.